Navigation Links
Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
Date:3/4/2009

losing (the "15-Month Preferred Stock Warrants"). All 35 investors elected the 15-Month Preferred Stock Warrants. Since the Company had agreed to register the shares of Common Stock underlying the 15-Month Common Stock Warrants, as a result of the investors' elections, the Company will not be registering shares of Common Stock underlying the 15-Month Common Stock Warrants.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical (primarily enzymatic) reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts in the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, and counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include statements regarding the sufficiency of the Company's cash resources to fund its planned operations through the second quarter of 2010, the Company's expectation that it's operating loss will continue to decrease to an average of less than $600,000 per quarter in 2009, the Co
'/>"/>

SOURCE Pressure BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
2. Pressure BioSciences, Inc. Issued First Patent in Canada
3. Interventional Cardiologists Nico Pijls, Bernard De Bruyne to Discuss Benefits of Measuring Coronary Pressure in Improving Multivessel PCI at ESC Congress 2007
4. Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320
5. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
6. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
7. Pressure BioSciences, Inc. Provides Corporate Update
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. The sensitive side of carbon nanotubes: Creating powerful pressure sensors
10. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
11. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... MENLO PARK, Calif. , July 23, 2014 /PRNewswire/ ... based investment firm, today announced the closing of Sofinnova ... $500 million and in excess of the initial fund ... on helping entrepreneurs build successful biotechnology companies. Consistent with ... companies with promising later stage clinical programs, along with ...
(Date:7/23/2014)... MD (PRWEB) July 23, 2014 a2z ... and ChirpE Mobile App, AACC Pathfinder, in its ... offerings. AACC’s annual meeting is planned for July 29-31, ... the place to be to connect with global leaders ... lab management, and other areas of breaking science in ...
(Date:7/22/2014)... 2014 The Board of Directors of BD (Becton, ... a quarterly dividend of 54.5 cents per common share payable ... 9, 2014. The indicated annual dividend rate is $2.18 per ... a leading medical technology company that partners with customers and ... evolving health needs. Our innovative solutions are focused on improving ...
(Date:7/22/2014)... Dr. Terry Baughn, a senior lecturer in mechanical engineering ... named Engineer of the Year by the North Texas ... , ASME has more than 130,000 members in 158 ... share technology to assist the engineering community, benefiting the ... the Texas Society of Professional Engineers honors banquet. Baughn ...
Breaking Biology Technology:Sofinnova Raises $500 Million Biotech Venture Fund 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3UT Dallas professor receives Engineer of the Year award 2
... Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased ... agreement with Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) ... to Lifeline Biotechnologies for a combination of stock, ... Endoscopy originally purchased the products from Lifeline Biotechnologies ...
... plc (LSE: SHP, NASDAQ: SHPGY ) announces ... Court of the Southern District of,New York against Mylan ... for infringement of Shire,s,patent: U.S. Patent No. 5,968,976 (",976 ... filed in response to an Abbreviated New Drug Application,("ANDA") ...
... 20 A new, innovative study,shows that a ... plus dexamethasone not only prevents chemotherapy-induced nausea,and vomiting ... oncology,patients. Data presented today at the ESMO Symposium ... New data presented today at ...
Cached Biology Technology:Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc. 2Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent 2Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent 3Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy 2Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy 3Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy 4
(Date:7/23/2014)... International Journal of Fuzzy Systems ( IJFS ), ... (TFSA). The cooperation will allow the journal to expand ... The International Journal of Fuzzy Systems is ... theory, design and application of fuzzy systems, soft computing ... hardware to software. Launched in 1999, the quarterly journal ...
(Date:7/23/2014)... German . , ... of which might be very different from ours. Some ... by sunlight in the atmosphere to calibrate their orientation ... Ornithology in Seewiesen, Germany, and Queen,s University Belfast have ... mammal, the greater mouse-eared bat, has the capability to ...
(Date:7/23/2014)... YORK, NY -- The New York Stem Cell Foundation ... to develop stem cell resources to investigate and explore ... Batten disease, a fatal illness affecting children. , NYSCF ... from skin samples of young people affected by juvenile ... cell lines are produced by artificially "turning back the ...
Breaking Biology News(10 mins):Bats use the evening sky's polarization pattern for orientation 2NYSCF partners with Beyond Batten Disease Foundation to fight juvenile Batten disease 2NYSCF partners with Beyond Batten Disease Foundation to fight juvenile Batten disease 3
... CHAMPAIGN, Ill. University of Illinois researchers are using ... weightiest questions in biology the relationship between cell mass ... computer engineering and bioengineering professor Rashid Bashir, published its results ... the National Academy of Sciences . "It,s merging micro-scale ...
... , LA JOLLA, CA-Fisetin, a naturally occurring compound ... slows the onset of motor problems and delays ... to researchers at the Salk Institute for Biological ... of Human Molecular Genetics , sets the ...
... ovarian cancer but new research from the Centenary Institute has ... new way that can break the resistance mechanism. Published ... (FTY720) had a potent effect in human ovarian cancer cells, ... chemotherapeutic drug currently available for the treatment of ovarian cancer. ...
Cached Biology News:Microsensors offer first look at whether cell mass affects growth rate 2Natural compound shows promise against Huntington's disease 2Natural compound shows promise against Huntington's disease 3New treatment to overpower drug resistance in ovarian cancer 2
Control primers and template for 5kb and 15 kb products....
Carrier Serum...
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: